Stay updated on Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    - Adds hepatocellular carcinoma as a topic on the page. Introduces a Genetic and Rare Diseases Information Center resource and updates the revision to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-21T08:45:15.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3; no study content or page functionality were altered.
    Difference
    0.0%
    Check dated 2026-03-06T19:27:02.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The study record shows new update timestamps in January and February 2026. Older update entries from 2025 were removed, indicating refreshed page information.
    Difference
    0.1%
    Check dated 2026-02-20T15:29:40.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.1 to v3.4.2; no visible changes to study data, eligibility criteria, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T07:31:57.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.4.0 to v3.4.1; no visible changes to page content or functionality, and to avoid alerts for small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-05T15:32:37.000Z thumbnail image
  9. Check
    69 days ago
    Change Detected
    Summary
    The page now shows a glossary and a 'Last Update Submitted that Met QC Criteria' field, and the FEAR Act label reads 'No FEAR Act Data' with a new revision 3.4.0. The previous capitalization and wording—'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'—along with revision 3.3.4 are removed.
    Difference
    0.1%
    Check dated 2026-01-29T07:33:32.000Z thumbnail image

Stay in the know with updates to Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelumab in Hepatocellular Carcinoma Clinical Trial page.